The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Coherus Biosciences Inc

Nasdaq: CHRS
Last

(U.S.) $26.95

Today's change0.00 0.00%
Updated September 1 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Coherus Biosciences Inc

Nasdaq: CHRS
Last

(U.S.) $26.95

Today's change0.00 0.00%
Updated September 1 4:00 PM -4GMT. Delayed by at least 15 minutes.

Coherus Biosciences Inc closed at (U.S.)$26.95.

Shares have lost 1.64% over the last five days, but have gained 65.13% over the last year to date. This security has outperformed the S&P 500 by 0.00% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $26.95
  • High--
  • Low--
  • Bid / Ask(U.S.) $23.14 / (U.S.) $0.00
  • YTD % change+65.13%
  • Volume0
  • Average volume (10-day)207,449
  • Average volume (1-month)221,883
  • Average volume (3-month)324,520
  • 52-week range(U.S.) $12.27 to (U.S.) $38.10
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$6.58
Updated September 1 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-388.43%

Although this company's net profit margin is negative, it is above the industry average and implies that Coherus Biosciences Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue76616
Total other revenue--------
Total revenue76616
Gross profit--------
Total cost of revenue--------
Total operating expense66433322
Selling / general / administrative9664
Research & development57362718
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-59-37-27-6
Interest income (expense), net non-operating0000
Gain (loss) on sale of assets--------
Other--------
Income before tax-59-41-29-8
Income after tax-59-41-29-8
Income tax, total------0
Net income-59-41-29-8
Total adjustments to net income--------
Net income before extra. items-59-41-29-8
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-59-41-29-8
Inc. avail. to common incl. extra. items-59-41-29-8
Diluted net income-59-41-29-8
Dilution adjustment--------
Diluted weighted average shares3833833
Diluted EPS excluding extraordinary itemsvalue per share-1.56-1.22-3.56-0.24
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-1.56-1.22-3.56-0.24